Hereditary angioedema: New hopes for an orphan disease

Israel Medical Association Journal

Volumn 10, Issue 12, 2008, Pages 850-855

  Reshef, Avner ^a,b   Leibovich, Iris ^a,b   Goren, Avner ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Bradykinin; C1 inhibitor; Heredita angioedema

Indexed keywords

ADRENALIN; ANDROGEN; ANTIHISTAMINIC AGENT; BERINERT P; BRADYKININ B2 RECEPTOR; CINRYZE; COMPLEMENT COMPONENT C1S INHIBITOR; CORTICOSTEROID DERIVATIVE; DANAZOL; ECALLANTIDE; FIRAZYR; FRESH FROZEN PLASMA; ICATIBANT; KALLIKREIN INHIBITOR; PLACEBO; RHUCIN; TRANEXAMIC ACID; UNCLASSIFIED DRUG; BRADYKININ; BRADYKININ RECEPTOR; DRUG DERIVATIVE; KALLIKREIN; PEPTIDE;

ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; BURNING SENSATION; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG HYPERSENSITIVITY; DRUG RECEPTOR BINDING; FAMILY; GENETIC DISORDER; HUMAN; INJECTION SITE ERYTHEMA; ISRAEL; LABORATORY TEST; LIVER TUMOR; PSYCHOSOCIAL CARE; QUALITY OF LIFE; RECURRENT DISEASE; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SUBSTITUTION THERAPY; SUPPORT GROUP; VIRILIZATION; CLASSIFICATION; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; FEMALE; MALE; MULTICENTER STUDY; NAUSEA; PATHOPHYSIOLOGY; REVIEW; TREATMENT OUTCOME;

ABDOMINAL PAIN; ANGIOEDEMA, HEREDITARY; BRADYKININ; CLINICAL TRIALS AS TOPIC; DOUBLE-BLIND METHOD; FEMALE; HUMANS; KALLIKREINS; MALE; MULTICENTER STUDIES AS TOPIC; NAUSEA; PEPTIDES; RECEPTORS, BRADYKININ; TREATMENT OUTCOME;

EID: 59449090645     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (40)

1. Cicardi M, Agostini A. Hereditary angioedema. N Engl J Med 1996;334:1666-7.
2. Davis AE III. Mechanisms of angioedema in first complement component inhibitor deficiency. Immunol Allergy Clin North Am 2006; 26:633-51.
3. Agostoni A, Cicardi M. Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine (Baltimore) 1992;71(4):206-15.
4. Weiler CR, Van Dellen RG. Genetic test indications and interpretations in patients with hereditary angioedema. Mayo Clinic Proc 2006;81(7):958-72.
5. Donaldson VH, Evans RR. A biochemical abnormality in hereditary angioneurotic edema: absence of serum inhibitor of C 1-esterase. Am J Med 1963;35:37-44.
6. Johnson AM, Alper CA, Rosen FS, Craig JM. C1 inhibitor: evidence for decreased hepatic synthesis in hereditary angioneurotic edema. Science 1971;173(996):553-4.
7. Prada AE, Zahedi K, Davis AE III. Regulation of C1-inhibitor synthesis. Immunobiology 1998;199:377-88.
8. Blanch A, Roche O, Urrutia I, Gambosa P, Fontan G, Lopez-Trascasa M. First case of homozygous C1 inhibitor deficiency. J Allergy Clin Immunol 2006;118:1330-5.
9. Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A. Plasma bradykinin in angio-oedema. Lancet 1998;351: 1693-7.
10. Bas M, Adams V, Suvorava T, Niehues T, Hoffmann TK, Kojada G. Nonallergic angioedema: role of bradykinin [Review]. Allergy 2007;62:842-56.
11. Zuraw BL. Clinical Practice: Hereditary angioedema. N Engl J Med 2008;359(10):1027-36.
12. Gompels MM, Lock RJ, Abinun M, et al. C1 Inhibitor deficiency: consensus document. Clin Exp Immunol 2005;139:379-94.
13. Bork K, Gul D, Hardt J, Dewald G. Hereditary angioedema with normal C1inhibitor: clinical symptoms and course. Am J Med 2007;120:987-92.
14. Alsenz J, Lambris JD, Bork K, et al. Autoantibody-mediated acquired deficiency of C1 inhibitor. N Engl J Med 1987;316:1630-66.
15. Fremeaux-Bacchi V, Guinnepain MT, Cacoub P, et al. Prevalence of monoclonal gammopathy in patients presenting with acquired angioedema type 2. Am J Med 2002;113:194-9.
16. Cacoub P, Fremeaux-Bacchi V, De Lacroix I, et al. A new type of acquired C1 inhibitor deficiency associated with systemic lupus erythematosous. Arthritis Rheum 2001;44(8):1836-40.
17. Miller DR, Oliveria SA, Berlowitz DR, Fincke BG, Stang P, Lillienfeld DE. Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors. Hypertension 2008;51(6): 1624-30.
18. Bork K, Meng G, Staubach P, Hardt J. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med 2006;119(3):267-74.
19. Bork K, Staubach P, Eckhardt AJ, Hardt J. Symptoms, course, and complications of abdominal attacks in hereditary angioedema due to C1 inhibitor deficiency. Am J Gastroenterol 2006;101:619-27.
20. Prior N, Remor E, Gomez-traseira C, et al. Development of a disease specific health-related quality of life (HRQOL) questionnaire in adults with hereditary angioedema due to C1 inhibitor deficiency (HAE). 5th C1 Inhibitor Deficiency Workshop. Budapest, 2007.
21. Frank MM. Hereditary angioedema. J Allergy Clin Immunol 2008;121: S398-401.
22. Farkas H, Varga L, Széplaki G, Visy B, Harmat G, Bowen T. Management of hereditary angioedema in pediatric patients. Pediatrics 2007;120(3):713-22.
23. Levi M, Choi G, Picavet C, Hack CE. Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency. J Allergy Clin Immunol 2006;117(4):904-8.
24. Guidelines on Treatment with Blood Components and Plasma Derivatives (in German). Federal Medical Council (Bundesarztekammer). 3rd edn. Cologne: Deutscher Artze-Verlag, 2003.
25. Bowen T, Cicardi M, Farkas H, et al. Canadian 2003 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. J Allergy Clin Immunol 2004;114:629-37.
26. Bowen T, Cicardi M, Bork K, et al. Hereditary angioedema: a current state-of-the-art review. VII: Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema. Ann Allergy Asthma Immunol 2008;100(1 Suppl 2):S30-40.
27. Bernstein JA. Hereditary angioedema: a current state-of-the-art review. VIII: Current status of emerging therapies. Ann Allergy Asthma Immunol 2008;100(1 Suppl 2 S41-6).
28. Cicardi M, Zingale L, Zanichelli A, Deliliers DL. Established and new treatments for hereditary angioedema: an update. Mol Immunol 2007;44:3858-61.
29. Zuraw BL. Hereditary angiodema: a current state-of-the-art review. IV: Short- and long-term treatment of hereditary angioedema: out with the old and in with the new? Ann Allergy Asthma Immunol 2008;100(1 Suppl 2):S13-18.
30. Markland W, Ley AC, Lander RC. Iterative optimization of high-affinity protease inhibitors using phage display. 2. Plasma kallikrein and thrombin. Biochemistry 1996;35:8058-67.
31. Han ED, MacFarlane RC, Mulligan AN, Scafidi J, Davis AE III. Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clil Invest 2002;109: 1057-63.
32. Bork K, Frank J, Grundt B, Schlattmann P, Nussberger J, Kreuz W. Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antaonist (Icatibant). J Allergy Clin Immunol 2007;119(6):1497-503.
33. Reshef A, Leibovich I. Icatibant, a new bradykinin B2 receptor antagonist, for acute hereditary angioedema attacks [Abstract]. J Allergy Clinical Immunol 2008;121(2):S102.
34. Schneider L, Lumry W, Vegh A, Williams AH, Shmalbach T. Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor. J Allergy Clin Immunol 2007;120:416-22.
35. Caballero T, Lopez-Serrano C. Anaphylactic reaction and antibodies to DX-88 (kallikerin inhibitor) in a patient with hereditary angioedema. J Allergy Clinical Immunol 2006;117:476-7.
36. Bork K. Pasteurized C1 inhibitor concentrate in hereditary angioedema: pharmacology, safety, efficacy and future directions. Expert Rev Clin Immunol 2008;4(1):13-20.
37. Cicardi M, Zingale LC, Zanichelli A, Deliliers DL, Caccia S. The use of plasma-derived C1 inhibitor in the treatment of hereditary angioedema. Expert Opin Pharmacother 2007;8(18):3173-81.
38. de Serres J, Gröner A, Lindner J. Safety and efficacy of pasteurized C1 inhibitor concentrate (Berinert P) in hereditary angioedema: a review. Transfus Apher Sci 2003;29(3):247-54.
39. Bernstein JA, Levy R, Wasserman RL, et al. Treatment of acute abdominal and facial attacks of hereditary angioedema (HAE) with human C1 esterase inhibitor (C1-INH): results of a global, multicenter, randomized, placebo-controlled, Phase II/III Study (I.M.P.A.C.T.1) [Abstract]. J Allergy Clin Immunol 2008;121(3):795.
40. Choi G, Soeters MR, Farkas H, et al. Recombinant human C1-inhibitor in the treatment of acute angioedema attacks. Transfusion 2007;47(6):1028-32.